Overheard: Houston-based BIPOC, female founder finalists of 2022 share challenges overcome

eavesdropping at the houston innovation awards gala

The five finalists in the BIPOC and Female-Founded Business categories for the Houston Innovation Awards share the challenges they have had to overcome. Photos courtesy

Houston is often lauded as one of the most diverse cities in America, and that diversity is seen across its business communities as well, which includes its innovation ecosystem.

Some of the BIPOC-Founded and Female-Founded Business category finalists from the Houston Innovation Awards Gala, which will be held on November 9, shared some of the challenges they faced being in the minority of their industries and careers.

"The biggest challenge I've faced as a female BIPOC founder is having to work 2 to 4 times harder to convince individuals that I am an expert in my field, and that I know what I'm talking about when it comes to my technology and implementation."

Photo courtesy

— Asma Mirza, CEO and co-founder of Steradian Technologies. "The way I overcame it was by showing irrefutable data to support my expertise and our invention, as well as hiring a diverse team that could substantiate our claims," she adds.

"As a female founder, I used to think that I was looked at as 'less than,' compared to my male counterparts. While I still struggle with this feeling,...  I decided that the biggest hinderance in my confidence as a female founder was the lies that I was telling myself."

Photo courtesy

— Megan Eddings, founder of Accel Unite. "I felt — and still sometimes do — insecure in a room filled with male founders, not because I thought I was any less-than, but because I was thinking they thought I was less-than — before ever even meeting me," Eddings added, sharing how she tries to change her own perspective. "I now feel a responsibility to share my story, as to show other women that they are not alone, their voice matters and to keep going."

"As a BIPOC founder, it was not easy in the beginning to find the connections and network with folks that had the resources to help us with our aspirations. That was the biggest challenge in getting started."

Photo courtesy

— Enrique Carro, CEO of Blue People. "Now that we have a few clients and testimonials, we are able to pull on them to help us find new clients and connections," he continues. "But this was something that we had to really work hard on at the beginning."

"One of my fears going into the fundraising process was being seen as too weak or too fragile to lead an early-stage venture."

Photo courtesy

— Joanna Nathan, CEO of Prana Thoracic, who shares she feels this way following the loss of her son. "I found that in being transparent with potential investors, after building some trust, and speaking openly about my loss and how it has inspired me to build this company, I was able to overcome this fear."

"The biggest challenge I’ve faced as a female founder comes down to resources. Finding the capital and time to get everything done is difficult for female founders because we have a lot on our shoulders and there are systemic inequalities that make things even more difficult."

Photo courtesy

— Allie Danziger, founder and CEO of Ampersand. "I’m creating a billion dollar company, but I’m a mom of two young girls, the executive director of one nonprofit and a board member of another, and a dependable friend, wife, daughter, sister and niece, too," she continues. "Other female founders and VCs are stretched, too, so it can be difficult to connect and find time to figure it out together. I have been very fortunate and also worked really hard to find both the time and resources to make it all work."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings